Stocks in the news, IPO offerings, IPO listing watchlist, corporate actions and more: your complete guide for the today!

Broadcom shares tumbled on Friday as investors balked at some disappointing aspects of the company's outlook heading into ...

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

Summary • Rigel Pharmaceuticals’ shares fell 11.8% to $43.13 amid disappointing Phase 1B study results for R289.• The study initially showed red blood cell transfusion independence in 33% of ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive investment.